Clinical Trials

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04739800 2026-04-13

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

120 enrolled 19 charts

GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT04293393 2026-03-12

CARABELA

Phase 2 Active not recruiting

200 enrolled 27 charts

Phase 3 Active not recruiting

Breast Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Phase 2/3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02502266 2026-03-05

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

582 enrolled 21 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03301350 2026-02-13

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

29 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05483933 2025-12-23

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Phase 1 Completed

86 enrolled 17 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02364713 2025-12-11

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

17 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Phase 2/3 Completed

260 enrolled 20 charts

Cystadenocarcinoma, Serous

NCT05613088 2025-10-20

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

106 enrolled 23 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05092360 2025-08-28

ARTISTRY-7

Phase 3 Terminated

456 enrolled 19 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04209855 2025-08-27

MIRASOL

453 enrolled 18 charts 2 FDA

Phase 1/2 Active not recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

17 enrolled 21 charts

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

348 enrolled 15 charts

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

NCT01818063 2025-04-30

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

9 enrolled 10 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EndocrineGynecologicNETThoracic

139 enrolled 14 charts

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT00170573 2024-12-16

Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

77 enrolled 9 charts

Ovarian Neoplasms

NCT02312245 2024-12-05

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

13 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05261490 2024-11-19

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

10 enrolled 21 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01696032 2024-08-27

SGI-110

120 enrolled 22 charts

Ovarian Neoplasms

NCT02606305 2024-06-14

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

264 enrolled 41 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT02456857 2024-02-13

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

17 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT03907969 2024-02-06

A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.

30 enrolled 17 charts

Advanced Malignancies

NCT01990352 2023-11-21

Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy

24 enrolled 5 charts

Breast Neoplasms

NCT00499083 2023-09-29

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

17 enrolled 5 charts

Breast Neoplasms

NCT00665457 2023-09-13

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

3 enrolled 6 charts

Breast Neoplasms

NCT02580058 2023-07-10

JAVELIN Ovarian 200

566 enrolled 40 charts

Ovarian Neoplasms

NCT00258960 2023-04-04

Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

49 enrolled 16 charts

Phase 2 Active not recruiting

Breast Neoplasms

NCT02315196 2023-03-29

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

62 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00129389 2023-03-07

FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients

1,925 enrolled 19 charts

Breast Neoplasms

NCT00608972 2023-02-08

Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer

31 enrolled 11 charts

Breast Neoplasms

NCT02186834 2023-01-04

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

28 enrolled 10 charts

Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01464593 2022-10-13

ABLATE

2 enrolled 5 charts

Gastrointestinal

Colonic Neoplasms, Liver Neoplasms

NCT02431559 2022-10-10

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

53 enrolled 22 charts

Ovarian Neoplasms

NCT02865811 2022-09-13

Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer

26 enrolled 19 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00976911 2022-06-21

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

361 enrolled 15 charts

Ovarian Neoplasms

NCT00785798 2022-04-04

Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas

17 enrolled 4 charts

Lymphoma

NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Phase 1 Completed

15 enrolled 18 charts

DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT01035658 2021-10-28

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

22 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00051311 2021-09-09

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

LymphoidOther hematologic neoplasmPlasma cell

62 enrolled 15 charts

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT01736943 2021-02-24

Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia

Other hematologic neoplasm

25 enrolled 9 charts

Leukemia, Myeloid, Acute

NCT00442260 2021-01-22

Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer

2 enrolled 1 chart

Breast Neoplasms

NCT03480750 2020-11-10

Trientine

18 enrolled 16 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00101010 2020-10-19

Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma

80 enrolled 7 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT02631876 2020-10-14

FORWARD I

366 enrolled 20 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00290433 2020-09-23

Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

55 enrolled 5 charts

Lymphoma

NCT00859495 2020-08-25

Trimodal Lung-Sparing Treatment of Pleural Mesothelioma

Other solid neoplasmThoracic

9 enrolled 4 charts

Mesothelioma, Malignant

NCT00985907 2020-06-17

DMV

13 enrolled 8 charts

Plasma cell

Multiple Myeloma, Patient Participation, Neoplasms, Plasma Cell

NCT00632827 2020-04-27

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

21 enrolled 13 charts

Lymphoma, T-Cell, Peripheral

NCT02421588 2020-04-03

CORAIL

442 enrolled 33 charts